Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...
Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...
Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions, including kidney stones (known as nephrolithiasis), prostate ...
10d
Safer Minimally Invasive Treatments in High-Risk & Comorbid Patients with Prostate Enlargement (BPH)
Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ageing men. As the prostate enlarges, it compresses the urethra and interferes ...
WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...
DUBLIN, Jan. 21, 2026 /PRNewswire/ -- ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced ...
The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.
One such change, often less spoken about, is the enlargement of the prostate gland. This condition, known as Benign Prostatic Hyperplasia (BPH), is extremely common, especially in men above 50 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results